The overview of modern approaches in treatment of triple negative breast cancer

By far the most aggressive subtype of breast cancer is triple negative cancer. The purpose of this review is to analyze current ideas about the pathogenesis, clinical characteristics of different subtypes of triple negative breast cancer, the nature of its metastasis, mechanisms of chemoresistance. The review presents the results of modern regimens of drug therapy of triple negative breast cancer according to the publications of domestic and foreign oncologists. On the basis of various clinical studies, the effectiveness of the use of anthracyclines, taxanes in the dose-dense regime, platinum preparations and other chemotherapy drugs for the treatment of triple-negative cancer has been shown. The presented treatment regimens allow to achieve a complete morphological response in 85% of patients, to increase the rates of relapse-free and overall survival, comparable with other subtypes of breast cancer. The review highlights the possibilities of modern targeted drugs-PARP inhibitors, chk1 inhibitors UCN‑01, immunotherapy possibilities for the treatment of this aggressive subtype of breast cancer.

triple negative breast cancer, chemotherapy, platinum drugs, anthracyclines, the dose-dense mode, BRCA associated breast cancer, tumor stems cells

1. The status of cancer care for the population of Russia in 2017. Edited by Kaprin AD, Starinskii VV, Petrova GV. Мoscow, 2018. (In Russian).

2. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 Nov 11; 363(20):1938–1948. https://doi.org/10.1056/NEJMra1001389

3. Poddubnaya IV, Karseladze DA. Clinical characteristics of triple negative breast cancer. Journal of N.N. Blokhin RCRC. 2010; 21(1(79):71–76.

4. Semiglazov VF, Semiglazov VV. Breast cancer treatment. Clinical and biological study. Moscow: SIMK, 2017.

5. Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009 Feb; 9(1):29–33. https://doi.org/10.3816/CBC.2009.n.005

6. Pak DD, Rasskazova EA, Danilova TV. Subtypes of breast cancer. Tumors of female reproductive system. 2012;(3–4):13–19.

7. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008 Dec 15; 14(24):8010– 8018. https://doi.org/10.1158/1078–0432.CCR 08–1208

8. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu M F, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008 May 7; 100(9):672–679. https://doi.org/10.1093/jnci/djn123

9. Battula VL, Shi Y, Evans KW, Wang R Y, Spaeth EL, Jacamo RO, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012 Jun 1; 122(6):2066– 2078. https://doi.org/10.1172/jci59735

10. Smirnova IA, Enileeva AA, Matchuk ON, Zamulaeva IA. Breast cancer and tumor stem cells. Review. The Bulletin «Radiation and Risk». 2016; 25(4):31–47. https://doi.org/10.21870/0131–3878– 2016–25–4-31–47

11. Shchepotin IB, Zotov AS, Lyubota RV, Anikus'ko NF, Lyubota II. The clinical significance of breast cancer stem cells (review of literature). Tumors of female reproductive system. 2014;(3):14–9.

12. Reuben JM, Lee B N, Gao H, Cohen EN, Mego M, Giordano A, et al. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44+CD24lo cancer stem cell phenotype. European Journal of Cancer. 2011 Jul 1; 47(10):1527–1536. https://doi.org/10.1016/j.ejca.2011.01.011

13. Sivak LA, Lyal'kin SA, Maidanevich NN, KlimanovMYu, Askol'skii AV, Kasap NV. Triple negative breast cancer: current view on the problem. Clinical Oncology. 2013; 3(11):60–62.

14. Manikhas AG, Babeshkin RN, Paltuev RM, Manikhas GM. The role of neoadjuvant chemotherapy of triple-negative breast cancer in St. Petersburg City Clinical Oncological Dispensary. Tumors of female reproductive system. 2016; 12(2):26–34. https://doi.org/10.17650/1994–4098–2016–12–2-26–34

15. Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2 mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. NatureMedicine. 2018 May; 24(5):628–637. https://doi.org/10.1038/s41591– 018–0009–7

16. Minckwitz G von, Blohmer J U, Raab G, Löhr A, Gerber B, Heinrich G, et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. AnnalsofOncology. 2005 Jan 1; 16(1):56–63. https://doi.org/10.1093/annonc/mdi001

17. Krivorot'ko PV, Zhil'tsova EK, Gigolaeva LP, KhadzhimatovaShM, Dashyan GA, Zernov KYu, et al. Comparative analysis of different neoadjuvant chemotherapy regimens for triple-negative breast cancer. Tumors of female reproductive system. 2017; 13(4):19–23. https://doi.org/10.17650/1994–4098–2017–13–4-19–23

18. Ignatova EO, Frolova MA, Petrovskii AV, Stenina MB, Glazkova EV, Krokhina OV, et al. evaluation of efficacy and toxicity of neoadjuvant chemotherapy with dose-dense doxorubicin, cisplatin, and paclitaxel in patients with early triple-negative breast cancer. Malignant tumors. 2016; 4(20):49–57. https://doi.org/10.18027/2224–5057–2016–4-49–57

19. Zikiryakhodzhaev AD, Frolova MA, Rasskazova EA, Glazkova EV. Treatment of Triple-Negative Breast Cancer. Tumors of female reproductive system. 2017; 13(2):20–26. https://doi. org/10.17650/1994–4098–2017–13–2-20–26

20. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, et al. Response to neoadjuvant therapy with cisplatin in BRCA1 positive breast cancer patients. BreastCancerResTreat. 2009 May 1; 115(2):359–363. https://doi.org/10.1007/s10549–008–0128–9

21. Minckwitz G von, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2 positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. TheLancetOncology. 2014 Jun 1; 15(7):747–756. https://doi.org/10.1016/S1470–2045(14)70160–3

22. Sekundova MA, Sdvizhkov AM, Borisov VI. New chemotherapy options for triple-negative breast cancer (review of literature). Journal of modern oncology. 2014; 16(1):7–12.

23. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla J P, Sami A, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10 year follow-up of the phase 3 randomised BCIRG 001 trial. TheLancetOncology. 2013 Jan 1; 14(1):72–80. https://doi.org/10.1016/S1470–2045(12)70525–9

24. Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O’Regan R, et al. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J ClinOncol. 2014 Aug 1; 32(22):2311–2317. https://doi.org/10.1200/JCO.2013.53.7142

25. Gerber B, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, et al. Neoadjuvant bevacizumab and anthracycline– taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44). JCO. 2011 May 20; 29(15_suppl):1006. https://doi.org/10.1200/jco.2011.29.15_suppl.1006

26. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V, et al. RIBBON 2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. JCO. 2011 Oct 11; 29(32):4286–4293. https://doi.org/10.1200/JCO.2010.34.1255

27. Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, et al. A Phase 1 trial of the poly (ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. EuropeanJournalofCancer. 2013 Sep 1; 49(14):2972–2978. https://doi.org/10.1016/j.ejca.2013.05.020

28. Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM. Upregulation of Poly (ADP-Ribose) Polymerase 1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. Genes&Cancer. 2010 Aug 1; 1(8):812–821. https://doi.org/10.1177/1947601910383418

29. Barton VN, Gordon MA, Richer JK, Elias A. Anti-androgen therapy in triple-negative breast cancer. TherAdvMedOncol. 2016 Jul; 8(4):305–308. https://doi.org/10.1177/1758834016646735

30. Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, et al. Targeting Chk1 in p53 deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J ClinInvest. 2012Apr 2; 122(4):1541–1552. https://doi.org/10.1172/JCI58765

31. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, et al. Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. JCO. 2010 Jun 7; 28(20):3256–3263. https://doi.org/10.1200/JCO.2009.24.4244

32. Mayer I, Burris H, Bendell J, Means-Powell J, Arteaga C, Shyr Y, et al. A Phase Ib Trial of RAD001, an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2 Negative Metastatic Breast Cancer. CancerRes. 2009 Dec 15; 69 (24 Supplement):3093. https://doi.org/10.1158/0008–5472.SABCS 09–3093

33. Ali HR, Provenzano E, Dawson S J, Blows FM, Liu B, Shah M, et al. Association between CD8+ T cell infiltration and breast cancer survival in 12 439 patients. AnnalsofOncology. 2014 Aug 1; 25(8):1536–1543. https://doi.org/10.1093/annonc/mdu191

34. Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, et al. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. JCO. 2016 Feb 4; 34(9):987–1011. https://doi.org/10.1200/JCO.2015.65.8427

35. Tsai M J, Chang W A, Huang M S, Kuo P L. Tumor Microenvironment: A New Treatment Target for Cancer. ISRN Biochem 2014. https://doi.org/10.1155/2014/351959

36. Ali HR, Chlon L, Pharoah PDP, Markowetz F, Caldas C. Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study. PLOS Medicine. 2016 Dec 13; 13(12): e1002194. https://doi.org/10.1371/journal.pmed.1002194

37. Khaitov RM, Kadaidze ZG. Immunity and cancer. Moscow. GEOTAR-Media, 2018.

38. Semiglazov VF, Tseluiko AI, Donskikh RV, Krivorot'ko PV, Dashyan GA, Semiglazov VV, et al. Future prospects for breast cancer immunotherapy. Medical Council. 2018;(19):12–16. https://doi.org/10.21518/2079–701X 2018–19–12–16

39. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014 Nov; 515(7528):558– 562. https://doi.org/10.1038/nature13904

40. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Neg ative Breast Cancer. N Engl J Med. 2018 29; 379(22):2108–2121. https://doi.org/10.1056/NEJMoa1809615

41. Protocol CO 41101 Double-blind placebo-controlled randomized phase III trial to study ipatasertib in combination with atezolizumab and paclitaxel in patients with locally advanced unresectable or metastatic triple negative breast cancer. Protocol SO 41101 number and date of RCT: No. 489 of 05.09.2019 F. Hoffmann-La Roche Ltd.

42. MO39196 Protocol a Multicenter randomized placebo-controlled phase III double-blind study of atezolizumab (PD-L1 antibody) in combination with paclitaxel compared to a combination of placebo and paclitaxel in patients with inoperable locally advanced or metastatic triple negative breast cancer for which no previous treatment has been performed. 01.08.2017– 01.05.2021. RCT #292 dated 30.05.2017.

43. Protocol BIG 16–05/AFT 27/WO39391 Multicenter randomized, open label phase III trial of atezolizumab (antibody to PD-L1) in combination with adjuvant chemotherapy in patients with operable triple negative breast cancer 06.07.2018–31.05.2022 RCT # 318 of 06.07.2018 F. Hoffmann-La Roche Ltd.